Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Red blood cell mediated drug delivery: Loading, release and clinical progress.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Co-Delivery of Ferrostatin-1 and M2 Macrophage-Derived Exosomal Signals via Engineered Hybrid Nanovesicles Enables Synergistic Neuroprotection in Traumatic Brain Injury.

ACS applied materials & interfaces·2026
Same author

Honeysuckle-derived vesicle-like nanoparticle and their hybrid vesicle as novel drug delivery systems for glioma therapy.

Colloids and surfaces. B, Biointerfaces·2026
Same author

Injectable self-healing hydrogel loaded with a self-assembling LL-37 derivative for treating infected skin wounds.

International journal of pharmaceutics·2026
Same author

Nanocarrier-based immunotherapy for viral diseases.

International journal of pharmaceutics: X·2025
Same author

A Novel Gelatinase-Responsive Self-Assembled Antimicrobial Peptide for Combating Drug-Resistant Bacterial Infection.

ACS applied materials & interfaces·2025

Related Experiment Video

Updated: Sep 9, 2025

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.1K

Targeted Reprogramming of Tumor Cells by Digoxin-Loaded Immunogenic Nanoparticles Enhances Immunity Against

Yuanyuan Meng1,2, Qi Ba2, Jiaxin Yao2

  • 1College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.

Advanced Healthcare Materials
|September 4, 2025
PubMed
Summary

This study introduces a novel nanoparticle strategy that turns tumor cells into a vaccine to enhance radiotherapy. This approach effectively inhibits tumor growth and metastasis, improving survival rates with minimal side effects.

Keywords:
abscopal effectantigen evasionimmunogenetic cell deathin situ vaccinationmetastasisradiotherapy

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Related Experiment Videos

Last Updated: Sep 9, 2025

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

11.1K
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K

Area of Science:

  • Oncology
  • Nanomedicine
  • Immunotherapy

Background:

  • Radiotherapy (RT) can induce an in situ vaccine effect.
  • Enhancing RT's in situ vaccine effect is crucial for treating disseminated tumors.
  • Current strategies often lack targeted delivery or controlled immunogenic cell death (ICD) induction.

Purpose of the Study:

  • To develop an "inflamed-cell-as-vaccine" strategy using nanoparticles to potentiate RT's in situ vaccine effect.
  • To engineer a tumor-targeting nanoparticle (rVAR2-M-NP) carrying a Digoxin-Ovalbumin (Dig-Ova) complex.
  • To evaluate the nanoparticle's ability to induce controlled ICD and enhance RT efficacy.

Main Methods:

  • Engineered biomimetic, tumor-targeting nanoparticles (rVAR2-M-NP) with Dig-Ova payload.
  • Investigated nanoparticle-induced immunogenic cell death (ICD) and cytokine expression.
  • Assessed nanoparticle effects on hypoxia-inducible factor-1α (HIF-1α) and susceptibility to RT in vitro and in vivo.
  • Combined nanoparticle treatment with RT, surgery, and anti-PD-1 immunotherapy.

Main Results:

  • rVAR2-M-NPs induced gentle ICD, transforming tumor cells into an "inflamed" state without direct cytotoxicity.
  • Enhanced expression of immunogenic cytokines and suppressed HIF-1α in tumor cells.
  • Increased tumor cell susceptibility to RT without elevating reactive oxygen species (ROS).
  • Combination therapy robustly inhibited primary tumor growth and metastasis in orthotopic 4T1 models.
  • Significantly improved survival outcomes with no notable side effects.

Conclusions:

  • Nanoparticle-delivered immunogens can induce controlled ICD, converting tumor cells into a potent cellular nanovaccine.
  • This strategy significantly enhances the therapeutic efficacy of RT-based immunotherapy.
  • The "inflamed-cell-as-vaccine" approach holds promise for stimulating systemic antitumor immunity.